CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen, a division of Life Technologies Corporation (NASDAQ:LIFE), today announced that its DynaChip® HLA Antibody Analysis System has received approval from Health Canada’s Medical Device Bureau for the detection and identification of antibodies to human leukocyte antigen (HLA) markers, which is an essential step in determining the compatibility of organ donors.
